P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE

• F. van Rhee,
• A. Rosenthal,
• K. Kanhai,
• R. Martin,
• K. Nishimura,
• A. Hoering,
• D. Fajgenbaum

Affiliations

F. van Rhee

1 University of Arkansas for Medical Sciences, Little Rock

A. Rosenthal

2 Cancer Research And Biostatistics, Seattle, United States of America

K. Kanhai

3 EUSA Pharma, Hemel Hempstead, United Kingdom

R. Martin

3 EUSA Pharma, Hemel Hempstead, United Kingdom

K. Nishimura

2 Cancer Research And Biostatistics, Seattle, United States of America

A. Hoering

2 Cancer Research And Biostatistics, Seattle, United States of America

D. Fajgenbaum

4 University of Pennsylvania, Philadelphia, United States of America